4d Molecular Therapeutics

(NASDAQ) FDMT

Current Price$8.83

Market Cap$461.60M

Since IPO (2020)-78%

5 Year-69%

1 Year+96%

1 Month-16%

4d Molecular Therapeutics Financials at a Glance

Market Cap

$461.60M

Revenue (TTM)

$88.24M

Net Income (TTM)

-$160.90M

EPS (TTM)

-$2.66

P/E Ratio

-3.31

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$8.83

Volume

560,414.198

Open

$9.00

Price

$8.83

Volume

560,414.198

Open

$9.00

Previous Close

$8.83

Daily Range

$8.83 - $9.38

52-Week Range

$3.68 - $12.34

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$8.83

Volume

560,414.198

Open

$9.00

Previous Close

$8.83

Daily Range

$8.83 - $9.38

52-Week Range

$3.68 - $12.34

Estimated Earnings Date

Aug 6, 2026

FDMT News

4dMT Revenue Jumps 200 Percent in Q2

Motley Fool Markets TeamAug 11, 2025

FDMT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About 4d Molecular Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

196

CEO

David H. Kirn, MD

Website

www.4dmoleculartherapeutics.com

Headquarters

EmeryVille, CA 94608, US

FDMT Financials

Key Financial Metrics (TTM)

Gross Margin

-12%

Operating Margin

-2%

Net Income Margin

-2%

Return on Equity

-35%

Return on Capital

-38%

Return on Assets

-31%

Earnings Yield

-30.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$461.60M

Shares Outstanding

52.28M

Volume

560.41K

Avg. Volume

757.39K

Financials (TTM)

Gross Profit

$77.58M

Operating Income

-$159.55M

EBITDA

-$132.48M

Operating Cash Flow

-$109.08M

Capital Expenditure

-$536.00K

Free Cash Flow

-$109.08M

Cash & ST Invst.

$402.66M

Total Debt

$21.41M

4d Molecular Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$3.05M

+21664.3%

Gross Profit

$992.00K

+102.4%

Gross Margin

32.56%

N/A

Market Cap

$461.60M

N/A

Market Cap/Employee

$2.03M

N/A

Employees

227

N/A

Net Income

-$68.76M

-43.3%

EBITDA

-$66.71M

-44.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$390.89M

+21.6%

Total Debt

$20.54M

-13.9%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$15.05M

-17.2%

Short Term Debt

$5.49M

-3.4%

Return on Assets

-31.37%

N/A

Return on Invested Capital

-38.24%

N/A

Free Cash Flow

-$68.13M

-40.8%

Operating Cash Flow

-$68.13M

-42.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PRTAProthena Corporation plc

PRTAProthena Corporation plc$8.25-0.12%

RGNXREGENXBIO Inc.

RGNXREGENXBIO Inc.$6.66+6.05%

NMRANeumora Therapeutics, Inc. Common Stock

NMRANeumora Therapeutics, Inc. Common Stock$1.78+0.00%

OMEROmeros Corporation

OMEROmeros Corporation$8.74-14.19%

BCYCBicycle Therapeutics plc

BCYCBicycle Therapeutics plc$4.05-1.22%

CMPXCompass Therapeutics, Inc.

CMPXCompass Therapeutics, Inc.$2.03+1.00%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$1.05-0.94%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$14.98+0.02%

INTCIntel

INTCIntel$124.57+0.07%

NOKNokia

NOKNokia$14.80+0.05%

NVDANvidia

NVDANvidia$205.19+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.59+0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$77.52+0.02%

SMCISuper Micro Computer

SMCISuper Micro Computer$30.46-0.05%

Questions About FDMT

What is the current price of 4d Molecular Therapeutics?

4d Molecular Therapeutics is trading at $8.83 per share.

What is the 52-week range for 4d Molecular Therapeutics?

Over the past 52 weeks, 4d Molecular Therapeutics has traded between $3.68 and $12.34.

How much debt does 4d Molecular Therapeutics have?

As of the most recent reporting period, 4d Molecular Therapeutics reported total debt of $20.54M.

How much cash does 4d Molecular Therapeutics have on hand?

4d Molecular Therapeutics reported $72.49M in cash and cash equivalents in its most recent financial results.

What is 4d Molecular Therapeutics’s dividend yield?

4d Molecular Therapeutics does not currently have a dividend yield.

4d Molecular Therapeutics

4d Molecular Therapeutics Financials at a Glance

FDMT News

4dMT Revenue Jumps 200 Percent in Q2

FDMT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About 4d Molecular Therapeutics

FDMT Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

4d Molecular Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About FDMT

What is the current price of 4d Molecular Therapeutics?

What is the 52-week range for 4d Molecular Therapeutics?

How much debt does 4d Molecular Therapeutics have?

How much cash does 4d Molecular Therapeutics have on hand?

What is 4d Molecular Therapeutics’s dividend yield?

Premium Investing Services